

KBP-2010-CPHG: Characteristics of 201 new cases of non-small cell lung cancer (NSCLC) with EGFR mutation

C. Locher, Meaux, France

*C. Neidhardt (Mulhouse), M. Boutemy (St-Quentin),
A. Belle (Compiègne), J. Crequit (Creil), A.-S. Blanchet-
Legens (Lyon), J.-Y. Tavernier (Douai), F. Steenhouwer
(Roubaix), H. Galloux (Quimper), M. Grivaux (Meaux)*

Conflicts of Interest

- No, real or perceived, conflicts of interest that relate to this oral presentation.
- However, over the past 5 years:
 - ✓ Have been principal investigator of clinical trials for several pharmaceutical companies
 - ✓ Have received honoraria or funding for attending conferences, communications, training, consulting, participation in expert groups
- Pharmaceutical companies:
 - ✓ Amgen, AstraZeneca, Boehringer Ingelheim, Caléa, Lilly, LVL Médical, Mundipharma, Orkyn, Oxyvie, Pierre Fabre, Roche, Vivisol

Introduction

- In France, in 2010, primary lung cancer remains a major concern
 - ✓ Incidence: 39,500 (male patients: 27,500; female patients: 12,000)
 - ✓ Mortality: 28,100 (male patients: 21,000; female patients: 7,100)
- Treatment of lung cancer is more personalized and adapted to the characteristics of the tumour, in particular to the presence of EGFR mutation


KBP-2010-CPHG: Description

- KBP-2010-CPHG:
 - ✓ Prospective, national epidemiological study promoted by the French College of General Hospital Respiratory Physicians (CPHG)
 - ✓ Primary objective: 5-year mortality in patients with primary lung cancer diagnosed in 2010 and followed up in a general hospital
- Slideshow objective:
Using KBP-2010-CPHG database,
 - ✓ To describe patients and tumour characteristics in patients with EGFR mutation exploration (explored patients)
 - ✓ To describe patients and tumour characteristics in patients with EGFR mutation (mutated patients)


KBP-2010-CPHG: Methods

- Inclusion criteria
 - ✓ Age \geq 18 years
 - ✓ Primary lung cancer diagnosed histologically or cytologically between 01-Jan-2010 to 31-Dec-2010 (date of sampling)
 - ✓ Followed up in the respiratory department of one of the participating French general hospitals
 - ✓ Oral informed consent
- A standardised form was completed for each patient
- Collected data: patient and tumour characteristics and management at inclusion
- A steering committee checked recruitment exhaustiveness



Study Population







Characteristics of patients explored for EGFR mutation




Characteristics of mutated patients









Conclusion

- EGFR-mutation exploration:
 - ✓ $\approx 30\%$ NSCLC patients
 - ✓ Adenocarcinoma, metastatic cancer
 - ✓ Women, never-smokers, young patients, and patients with good performance status
- ➔ High rate of EGFR-mutation tests
- ➔ Respect of current French guidelines
- ➔ Influence of patient's phenotype on EGFR-mutation exploration
- EGFR mutation:
 - ✓ $\approx 10\%$ explored NSCLC patients
 - ✓ Women, non-smokers, adenocarcinomas
- ➔ Consistent with results of the literature
- $\approx -20\%$ in 1-year mortality in patients with EGFR-mutation
- ➔ Need to be further analysed in particular to evaluate the role of targeted therapy

16 Amsterdam, 29 September 2013

KBP-2010 - CPHG

Acknowledgments

Scientific committee	<ul style="list-style-type: none">• M Grivaux, Meaux (<i>chairman</i>)• C Locher, Meaux (<i>secretary</i>); D Debieuvre, Mulhouse (<i>secretary</i>)• B Asselain, Paris; F Blanchon, Meaux; D Coëtmeur, St-Brieuc; T Collon, Montfermeil; C Dayen, St-Quentin; F Goupil, Le Mans; J Le Treut, Aix en Provence; F Martin, Compiègne; O Molinier, Le Mans
Investigators	<ul style="list-style-type: none">• Lung specialists practising in the Respiratory Medicine Department of the 119 General Hospital involved in the KBP-2010-CPHG study
Funding	<ul style="list-style-type: none">• Recherche en santé respiratoire (<i>fonds de dotation</i>), Pneumologie développement, CNMRT, AstraZeneca, Boehringer Ingelheim, Chugai, GlaxoSmithKline, Lilly, Pfizer, Pierre Fabre, Roche, sanofi aventis